Novo Nordisk A/S (NYSE:NVO) Receives $81.00 Average PT from Analysts

Shares of Novo Nordisk A/S (NYSE:NVO) have received an average rating of “Hold” from the sixteen analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $81.00.

NVO has been the topic of several recent analyst reports. UBS Group cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 20th. TD Cowen cut their price objective on Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, August 19th. BNP Paribas Exane raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price for the company in a report on Wednesday, August 13th. Finally, Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors have recently modified their holdings of NVO. Kingstone Capital Partners Texas LLC raised its holdings in Novo Nordisk A/S by 301,443.6% during the second quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock worth $690,560,000 after purchasing an additional 10,001,898 shares during the last quarter. Nuveen LLC purchased a new position in shares of Novo Nordisk A/S in the first quarter valued at $370,272,000. Nuveen Asset Management LLC raised its stake in shares of Novo Nordisk A/S by 73.2% during the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company’s stock worth $537,189,000 after buying an additional 2,639,693 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter worth about $158,657,000. Finally, Amundi boosted its position in shares of Novo Nordisk A/S by 49.1% in the 1st quarter. Amundi now owns 4,938,507 shares of the company’s stock worth $331,576,000 after buying an additional 1,627,051 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $56.49 on Thursday. The stock has a market capitalization of $252.21 billion, a P/E ratio of 15.52, a P/E/G ratio of 1.92 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $139.74. The company’s fifty day moving average is $61.43 and its two-hundred day moving average is $68.82.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were given a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio is presently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.